

**The final version of this paper was published in:**

**Journal of Paediatrics and Child Health 2015;51(10):1023-9.**

**Oesophageal atresia and tracheo-oesophageal fistula in Western Australia:  
prevalence and trends**

Emanuele Leoncini,<sup>1</sup> Carol Bower,<sup>1,2</sup> Natasha Nassar<sup>3</sup>

1. Telethon Kids Institute, University of Western Australia, Perth, Western Australia
2. Western Australian Register of Developmental Anomalies, Perth, Western Australia
3. Clinical and Population Perinatal Health Research, Kolling Institute of Medical Research,  
University of Sydney, Australia

**Corresponding author**

Natasha Nassar

Uni Dept O&G, Building 52

Royal North Shore Hospital

St Leonards NSW 2065 AUSTRALIA

Ph: +61 2 9462-9792

Fax: +61 2 9462-9058

Email: [natasha.nassar@sydney.edu.au](mailto:natasha.nassar@sydney.edu.au)

## **Abstract**

### **Background**

A recent international study reported a higher prevalence of oesophageal atresia with or without tracheo-oesophageal fistula (OA±TOF) in Western Australia (WA). The aim of this study was to examine the prevalence and trends of OA and/or TOF in WA; determine the proportion of cases with associated anomalies; and explore the impact of time of diagnosis.

### **Methods**

The study population comprised all infants born in WA, 1980-2009 and registered with OA and/or TOF on the WA Register of Developmental Anomalies (WARDA).

### **Results**

OA±TOF and TOF alone affect, on average, 1 in every 2,927 births in WA, with a total prevalence of 3.00 and 0.42 per 10,000 births, respectively. The prevalence of OA±TOF increased by 2.0% per annum, with only cases with associated anomalies (64% of cases) demonstrating an increase. TOF rates were stable. Among OA±TOF infants, the proportion of livebirths, stillbirths and elective terminations of pregnancy for fetal anomaly (TOPFA) was 79%, 6% and 15%, respectively; while the majority (94%) of TOF only cases were livebirths. In 2000-2009 there was 30% fall in OA±TOF livebirths with 61 (58%) cases diagnosed in first week of life, 10 (9%) prenatally and 34 (32%) at postmortem only.

### **Conclusions**

A higher prevalence of OA±TOF in WA was observed with increase over time attributable to increase with associated anomalies. Consistent reporting, availability of prenatal diagnosis and ascertainment of cases following TOPFA or post-mortem examinations can significantly affect prevalence of OA and/or TOF.

## INTRODUCTION

Oesophageal atresia and tracheo-oesophageal fistula are the most common anomalies of the oesophagus and trachea. Oesophageal atresia is a congenital anomaly of the upper gastrointestinal tract characterised by the complete discontinuity of the oesophagus with or without an abnormal connection between the oesophagus and the trachea (OA±TOF). Tracheo-oesophageal fistula (TOF) can also occur without oesophageal atresia and accounts for 7-18% of all congenital tracheo-oesophageal malformations.<sup>1-5</sup> Infants are diagnosed either prenatally or, in most cases, at birth and require surgical repair in the first few days of life. The aetiology of OA and/or TOF is still unclear and is considered to be multifactorial.<sup>2,3,6,7</sup>

Large variations in prevalence of OA±TOF across different geographical regions have been reported, although no changes in prevalence over time have been observed. The overall prevalence of OA±TOF in 23 European registries of congenital anomalies during 1987-2006 was 2.43 per 10,000 births, ranging from 1.27 to 4.55, with no differences in the prevalence over time.<sup>8</sup> The estimated national prevalence of OA±TOF reported by the US National Birth Defects Prevention Network, based on data from 14 population-based birth defects registries, was 2.17 per 10,000 births for the period from 2004 to 2006.<sup>9</sup> For this study, cases included OA and/or TOF and oesophageal stenosis. Similarly, a recent international study among 18 birth defects surveillance programs in Europe, the Americas and Australia reported an overall prevalence of OA±TOF of 1 in 4,099 (2.44 per 10,000) births.<sup>10</sup> Although there was no evidence of a significant linear trend among any of the member programs, there was both a higher prevalence, particularly of TOF alone, and increase in cases in Western Australia during the period of study, 1998 to 2007.

Several factors may influence reporting and registration of congenital anomalies including: screening policies and procedures, clinician skills, timing of fetal anomaly screening, subsequent availability and timing of elective termination of pregnancy, and autopsy policies.<sup>11</sup> Thus, a number

of factors may explain the higher observed rates of OA and/or TOF in Western Australia; including multiple sources of notification, inclusion of cases following termination of pregnancy or post-mortem examinations, availability of prenatal diagnosis and higher age of registration up to six years.<sup>11-13</sup> Only tabulated data were available for the international study. Individual information regarding timing and age of diagnosis, specific source of notification, whether cases were isolated or associated with multiple anomalies and whether there have been changes in diagnosis and reporting over time would provide further insight regarding ascertainment and reporting of cases, and possibly the underlying aetiology of these conditions.

The frequency of additional anomalies in previous population-based investigations reporting OA and/or TOF have ranged between 43 and 63%.<sup>1,4,5,8,14-19</sup> Congenital heart disease is the most commonly associated congenital anomaly and the proportion reported with chromosomal anomalies is 5-10%.<sup>1,4,8,14-20</sup> OA and/or TOF are more likely to be diagnosed in conjunction with many syndromes, sequences and associations; with the most common being VACTERL association.<sup>19</sup>

The aim of this study was to examine the birth prevalence and trends of OA and/or TOF in Western Australia; determine the proportion of cases with isolated and multiple anomalies; and explore the impact of different sources and timing of diagnosis on rates.

## **METHODS**

Western Australia is a geographically well defined area, with a population of 2.3 million, the majority of whom live in the Perth metropolitan area. There are approximately 31,000 births per year. Cases of OA and/or TOF were identified from the Western Australian Register of Developmental Anomalies (WARDA), a population-based notification system of malformations established in 1980.<sup>11</sup> The WARDA draws on multiple sources of notification including hospitals and private practitioners, Western Australian Department of Health databases (midwives', mortality and hospital morbidity systems) and investigative and treatment centres. All fetuses and neonates diagnosed with OA and/or TOF in Western Australia from January 1980 to December 2009 inclusive, were identified from the WARDA, including stillbirths of 20 weeks' gestation or more, terminations of pregnancies for fetal anomaly of any gestation (TOPFA) and liveborn children up to six years of age. Timing and age of diagnosis was also identified and may have been prenatally from antenatal ultrasound, in first few weeks of life or later or at post mortem.

Each individual birth defect is coded by the WARDA according to the British Paediatric Association International Classification of Diseases, 9<sup>th</sup> revision system (BPA-ICD9), with up to ten diagnostic categories available to allow coding of multiple anomalies per case. The following codes were used to identify the diagnosis of OA: 750.30, OA+TOF: 750.31; and TOF alone: 750.32. All records were reviewed and classified into one of four groups as: 1) isolated cases, if OA±TOF or TOF alone were the only defects present; 2) cases with non-syndromic multiple congenital anomalies when one or more additional non-oesophageal malformations were recognised; 3) cases with non-chromosomal recognised conditions including syndrome, sequence, association and spectrum disorders; and 4) cases with chromosomal anomalies. Congenital anomalies in cases with non-syndromic multiple anomalies were also classified by organ system.

Total birth prevalence (and 95% confidence interval) and trends over time of OA±TOF and TOF, and by birth outcome and age at diagnosis were examined. Birth prevalence was defined as the total number of cases among live births, stillbirths and TOPFA divided by the sum of live births and stillbirths in the Western Australia population and expressed per 10,000 births. Denominator data were obtained from the Western Australia Department of Health and consisted of all live births and stillbirths of 20 weeks' gestation or more born in Western Australia. Annual, decade-specific (1980-1989, 1990-99, 2000-2009) and overall prevalence were calculated. The Cochran-Armitage test<sup>21</sup> was used to evaluate homogeneity and time trend in prevalence for OA±TOF and TOF alone, in both isolated cases and cases with associated anomalies. To allow for rare events and variation in births over time, Poisson regression with an offset term was used to assess the trend and calculate the average annual change in prevalence over the study period. Prevalence was also examined by birth outcomes classified as live births, stillbirth or TOPFA; and age at first diagnosis (prenatal, within first week of life, after first week of life, postmortem). Statistical analyses were performed using Stata 11.2 (Stata Corporation, College Station, TX). Ethics approval for access to data and to conduct the study was obtained from the Western Australian Department of Health Human Research Ethics Committee.

## RESULTS

A total of 260 cases of OA and/or TOF were notified to the WARDA out of 761,247 births in the 30-year period from 1980-2009, yielding an overall prevalence of 3.42 cases per 10,000 births (95%CI 3.01-3.86). Annual number of births increased from approximately 21,000 in 1980 to 31,000 in 2009. Of the 228 OA±TOF cases (3.00 per 10,000 births; 95%CI 2.62-3.41), OA with TOF comprised 202 (89%) of the cases and 26 (11%) had OA without TOF. The percentage of OA alone decreased over the three decades (14.8%, 9.8%, and 10.4% for 1980-1989, 1990-1999 and 2000-2009, respectively). The proportion and trend in the prevalence of OA+TOF increased, on average, by 2.0% per year (95%CI 1.0-4.0%,  $P<0.01$ ) from 2.23 (95%CI 1.66-2.92) to 2.16 (95%CI 1.63-2.81) to 3.48 per 10,000 births (95%CI 2.82-4.26) over the three decades, respectively (Figure 1).

There were 32 cases of TOF alone identified in Western Australia, 1980-2009 resulting in a prevalence of 0.42 per 10,000 births (95%CI 0.29-0.59). Despite the small numbers, the trend in the prevalence of TOF alone was relatively stable over time ( $P=0.98$ ) (Figure 1).

Among the 228 cases of OA±TOF, 180 resulted in a live birth (79%, 2.36 per 10,000 births), 14 (6%) were stillbirths and 34 (15%) were TOPFA. Over the three decades, the proportion of livebirths decreased by a third to 66%, while in 2000-2009, 9% of cases diagnosed were stillbirths and almost a quarter (24%) were TOPFA. In contrast, the majority of cases of TOF alone were livebirths ( $n=30$ , 94%).

In 2000-2009, there were 60 (63%) cases of OA+TOF cases diagnosed in the first week of life, most of them at birth. In 7 cases (7%) the diagnosis was made prenatally, in 1 case (1%) after the first week of life, and in 27 cases (28%) the diagnosis was first made postmortem (Table 1). In contrast, two-thirds (64%) of OA alone were first diagnosed at postmortem. Table 1 highlights the

increase in prenatal detection and post mortem diagnoses for OA±TOF cases over the study period, with a corresponding decrease in the proportion of cases diagnosed in first week of life. During 2000-2009, the majority (82%) of TOF only cases were diagnosed in first week of life, 9% prenatally and 9% after the first week.

Only one-third (n=72, 36%) of OA+TOF cases were isolated and the remaining 130 had associated anomalies; including 21 (10%) with chromosomal abnormalities, 50 (25%) had non-chromosomal recognized conditions, of which 40 (20%) were diagnosed with VACTERL association, and 59 (29%) had non-syndromic multiple congenital anomalies (Table 2). The most common additional structural anomalies were those of the cardiovascular and musculoskeletal system, present in 17.8% and 11.4% of cases, respectively. Infants diagnosed with OA alone had a similar proportion of non-syndromic and non-chromosomal conditions, but a lower proportion were isolated (19%) and a higher percentage were diagnosed with chromosomal anomalies (n=6, 23%), but numbers were small (Table 2). Of the 32 cases of TOF alone, 17 were isolated (53%), 6 (19%) had multiple anomalies and 7 (22%) had a VACTERL association (Table 2).

For all cases of OA±TOF, the total prevalence of isolated cases was 1.01 per 10,000 births (95%CI 0.80-1.26); increasing slightly from 1.03 (95%CI 0.66-1.53) in 1980-89 to 1.25 per 10,000 births (95%CI 0.86-1.74) in 2000-09 (P=0.17) (Figure 2). For cases with associated anomalies the overall prevalence was 1.98 (95%CI 1.68-2.33) per 10,000 births; increasing, on average, by 3.0% per annum (P<0.01) from 1.58 (95%CI 1.12-2.18) to 1.65 (95% CI 1.19-2.23), and 2.64 per 10,000 (95%CI 2.07-3.32) over the study decades (Figure 2). Overall, the ratio of isolated to associated anomalies did not vary significantly or show a trend across the three time periods (ratio 0.65 in 1980-89, 0.45 in 1990-99, and 0.47 in 2000-09).

## DISCUSSION

OA±TOF and TOF alone affect, on average, 1 in every 2,927 births in Western Australia, with a total prevalence of 3.00 for OA±TOF and 0.42 for TOF alone per 10,000 births. The prevalence of OA±TOF in Western Australia has increased by 2% per annum over the 30-year period, from 1980 through 2009. However, when cases were subdivided by isolated and associated anomalies, only the associated OA±TOF group demonstrated a significant increase. Furthermore, results reveal that there was a 30% fall in livebirth cases offset by an increase in the proportion of cases diagnosed following stillbirth or TOPFA.

In this study we found a higher prevalence of OA±TOF (3.42 per 10,000) compared to that reported in three recent studies; of 2.44 per 10,000 births by the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR),<sup>10</sup> 2.46 per 10,000 births by EUROCAT, the European surveillance of congenital anomalies<sup>8</sup> and 2.17 per 10,000 births by the National Birth Defects Prevention Network in the US.<sup>9</sup> Findings suggest increased case ascertainment in Western Australia with additional information obtained from post mortem reports most likely to explain higher rates. The prevalence reported in this study is also higher than that reported for Western Australia in the ICBDSR study (2.63 per 10,000 births)<sup>10</sup> and is due to a misclassification of TOF alone, which were identified on post mortem to also have OA.

Our findings reveal one-quarter of OA±TOF and TOF to be associated with non-chromosomal recognized conditions, considerably higher than rates of around 7-17% found in previous studies.<sup>4,8</sup> The most common associated anomaly was VACTERL association which was present in about 20% of cases, with the percentage the same in patients with OA±TOF and TOF alone. The reported percentage of VACTERL association in patient with OA and/or TOF in population-based studies varies, ranging from 2-10%,<sup>4,8,19</sup> however, studies from single institutions report either a similar percentage to our finding<sup>22</sup> or higher.<sup>23</sup>

Although we found an increasing prevalence of OA±TOF over the 30-year period, 1980-2009, this trend was observed in non-isolated cases only. No overall change in trends was observed in the EUROCAT study during 1987-2006<sup>8</sup> or the ICBDSR study for 1998-2007.<sup>10</sup> Our results suggest that the causative factors are due to either increased reporting and ascertainment; or attributable to underlying aetiological factors affecting embryonic fetal development more generally and are not just restricted to the gastrointestinal system. An increase in ascertainment of cases over time may be one factor contributing to both the higher proportion of and rising trend of OA±TOF with associated anomalies. However, given the WARDA has multiple sources of notification with no major change in data collection or registration of cases over the last 30 years; and that oesophageal anomalies are a serious condition, diagnosed early in life, it is unlikely these cases will be missed, and increasing trends may be real.

Findings highlight increasing proportion of cases diagnosed following termination of pregnancy for fetal anomaly and following post mortem resulting from improved availability, ascertainment and reporting of these occurrences. Previous studies have shown that the rate of termination of pregnancy is higher for cases with chromosomal or additional congenital anomalies than for cases with an isolated anomaly.<sup>12</sup> Increases in the prevalence of chromosomal and syndromic anomalies diagnosed over the last few decades may be a result of increased detection and reporting in Western Australia with higher proportion of all types of associated anomalies; including chromosomal, non-chromosomal and non-syndromic anomalies diagnosed compared with previous reports.<sup>1,4,8,14-20</sup> This is also affirmed by our finding of higher rates of stillbirths and terminations of pregnancies among cases, which are more likely to occur among those with associated anomalies and availability of ascertainment via prenatal diagnosis, postmortem assessment and ample period of follow-up.<sup>24</sup> In addition, the WARDA also assign age at diagnosis for each specific anomaly diagnosed in each infant compared with other studies that classify an overall or first time of

diagnosis. For example, those cases terminated for chromosomal anomaly will have that specific anomaly diagnosed prenatally; while an oesophageal anomaly diagnosed post mortem will be assigned as such. This may explain our higher proportion of cases diagnosed post mortem (20%) and fewer prenatally (8%) compared with EUROCAT study reporting a 33% prenatal detection rate.<sup>8</sup>

An increase in underlying aetiological factors associated with chromosomal and non-chromosomal syndromes or associations, in general, may also be implicated. Potential factors attributed to their rise have also been linked with increased risk of oesophageal defects and include older maternal age,<sup>16,25</sup> maternal medical conditions,<sup>26-28</sup> and multiple pregnancies. Of interest is a recent study demonstrating a consistent association between pre-gestational diabetes and cases with oesophageal defects and associated congenital anomalies, irrespective of maternal BMI.<sup>27</sup> Greater use of assisted reproductive technology (ART) over the last 20 years may have also contributed to the increasing prevalence. ART is associated with increased risk of birth defects compared with births from spontaneous conception.<sup>29-34</sup>

Due to limited data, we were unable to explore the association and contribution of these and other parental, genetic and environmental factors to rates and trends of OA±TOF in Western Australia, all of which require thorough assessment in future studies. Despite the increase in associated anomalies, we found the ratio of isolated to associated anomalies (~0.45) did not change over the last 20 years. An unequal distribution in oesophageal defects was previously reported<sup>3,35,36</sup> but not in the study by Torfs et al,<sup>4</sup> where the proportion of associated anomalies didn't vary substantially between oesophageal defects. One of the key explanations for the unequal distribution was attributed to delay in diagnosis.<sup>36</sup> However, given the WARDA includes anomalies diagnosed up to the age of 6 years, this hypothesis is not valid for this setting.<sup>11,24</sup>

In regards to the prevalence of TOF alone, results in the present study do not differ significantly from the reported prevalence in the literature. Three US studies reported the prevalence of TOF to be between 0.16 and 0.52 per 10,000 births,<sup>4,14,37</sup> EUROCAT found a prevalence of 0.26 in 6 centres,<sup>1</sup> and the ICBDSR<sup>10</sup> showed a total prevalence of 0.22 per 10,000 births. Although the Western Australian prevalence reported in the latter study was high (1.3 per 10,000 births) this has now dropped due to the review and additional diagnosis of OA from post mortem reports and reclassification of cases to OA±TOF. A much lower proportion of associated anomalies was also observed in infants with TOF without atresia.

The strengths of this study are that it is a population-based study with prospective data collection and congenital anomalies diagnosed prenatally and up to the age of 6 years are included.<sup>11,24</sup> The WARDA uses multiple sources for active case ascertainment and cases comprise anomalies occurring in livebirths, stillbirths and in pregnancies terminated because of fetal anomaly. Given that oesophageal defects are more likely to be diagnosed in conjunction with other anomalies as chromosomal, syndromes, associations or multiple anomalies without a pattern,<sup>2,3,20</sup> that may result in termination of pregnancy, a complete ascertainment of all terminations for fetal anomaly as well as an accurate postmortem diagnosis is also necessary to provide reliable baseline data on the prevalence of oesophageal defects. This comprehensive approach is demonstrated when comparing our prevalence of OA±TOF (3.42) with that from a recent national French study, reporting a rate of 1.8 per 10,000 births where only live birth cases were included.<sup>13</sup>

In summary, we found a higher and increasing prevalence of OA±TOF diagnosed in Western Australia over the last 30 years compared with studies elsewhere. Findings suggest the trend is attributable to an increase in the proportion of infants with associated anomalies, particularly chromosomal and non-chromosomal cases with an association or syndrome. Separating effects of increased prevalence attributable to improved reporting and ascertainment of associated anomalies

and underlying aetiological factors is difficult, but important. Future studies disentangling and taking these factors into account are essential to contribute to our understanding of the underlying aetiology and impact of oesophageal anomalies.

## **ACKNOWLEDGEMENTS**

The authors wish to acknowledge the valuable work of the WARDA staff, Edwina Rudy, Ann Callaghan, Jennifer Quick, and Alison Rowley; and thank Peter Cosgrove for his assistance with database management.


## REFERENCES

1. Depaepe A, Dolk H, Lechat MF. The epidemiology of tracheo-oesophageal fistula and oesophageal atresia in Europe. EUROCAT Working Group. *Arch Dis Child* 1993; **68**(6): 743-8.
2. Shaw-Smith C. Oesophageal atresia, tracheo-oesophageal fistula, and the VACTERL association: review of genetics and epidemiology. *J Med Genet* 2006; **43**(7): 545-54.
3. Spitz L. Oesophageal atresia. *Orphanet J Rare Dis* 2007; **2**: 24.
4. Torfs CP, Curry CJ, Bateson TF. Population-based study of tracheoesophageal fistula and esophageal atresia. *Teratology* 1995; **52**(4): 220-32.
5. Yang P, Khoury MJ, Stewart WF, et al. Comparative epidemiology of selected midline congenital abnormalities. *Genet Epidemiol* 1994; **11**(2): 141-54.
6. Felix JF, de Jong EM, Torfs CP, de Klein A, Rottier RJ, Tibboel D. Genetic and environmental factors in the etiology of esophageal atresia and/or tracheoesophageal fistula: an overview of the current concepts. *Birth Defects Res A Clin Mol Teratol* 2009; **85**(9): 747-54.
7. Felix JF, Tibboel D, de Klein A. Chromosomal anomalies in the aetiology of oesophageal atresia and tracheo-oesophageal fistula. *Eur J Med Genet* 2007; **50**(3): 163-75.
8. Pedersen RN, Calzolari E, Husby S, Garne E. Oesophageal atresia: prevalence, prenatal diagnosis and associated anomalies in 23 European regions. *Arch Dis Child* 2012; **97**(3): 227-32.
9. Parker SE, Mai CT, Canfield MA, et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. *Birth Defects Res A Clin Mol Teratol* 2010; **88**(12): 1008-16.
10. Nassar N, Leoncini E, Amar E, et al. Prevalence of esophageal atresia among 18 international birth defects surveillance programs. *Birth Defects Res A Clin Mol Teratol* 2012; **94**(11): 893-9.
11. Bower C RE, Callaghan A, et al. Report of the Birth Defects Registry of Western Australia 1980-2010. Subiaco, Australia: King Edward Memorial Hospital, Centre for Women's Health. Number 18. 2011  
([www.kemh.health.wa.gov.au/services/register\\_developmental\\_anomalies/documents-](http://www.kemh.health.wa.gov.au/services/register_developmental_anomalies/documents-) accessed February 2014)
12. Garne E, Loane M, Dolk H. Gastrointestinal malformations: impact of prenatal diagnosis on gestational age at birth. *Paediatr Perinat Epidemiol* 2007; **21**(4): 370-5.
13. Sfeir R, Bonnard A, Khen-Dunlop N, et al. Esophageal atresia: data from a national cohort. *J Pediatr Surg* 2013; **48**(8): 1664-9.
14. Forrester MB, Merz RD. Epidemiology of oesophageal atresia and tracheo-oesophageal fistula in Hawaii, 1986-2000. *Public Health* 2005; **119**(6): 483-8.

15. Harris J, Kallen B, Robert E. Descriptive epidemiology of alimentary tract atresia. *Teratology* 1995; **52**(1): 15-29.
16. Oddsberg J, Jia C, Nilsson E, Ye W, Lagergren J. Maternal tobacco smoking, obesity, and low socioeconomic status during early pregnancy in the etiology of esophageal atresia. *J Pediatr Surg* 2008; **43**(10): 1791-5.
17. Robert E, Mutchinick O, Mastroiacovo P, et al. An international collaborative study of the epidemiology of esophageal atresia or stenosis. *Reprod Toxicol* 1993; **7**(5): 405-21.
18. Sparey C, Jawaheer G, Barrett AM, Robson SC. Esophageal atresia in the Northern Region Congenital Anomaly Survey, 1985-1997: prenatal diagnosis and outcome. *Am J Obstet Gynecol* 2000; **182**(2): 427-31.
19. Stoll C, Alembik Y, Dott B, Roth MP. Associated malformations in patients with esophageal atresia. *Eur J Med Genet* 2009; **52**(5): 287-90.
20. Genevieve D, de Pontual L, Amiel J, Sarnacki S, Lyonnet S. An overview of isolated and syndromic oesophageal atresia. *Clin Genet* 2007; **71**(5): 392-9.
21. Agresti. Categorical data analysis. 2nd ed; 2002.
22. Driver CP, Shankar KR, Jones MO, et al. Phenotypic presentation and outcome of esophageal atresia in the era of the Spitz classification. *J Pediatr Surg* 2001; **36**(9): 1419-21.
23. de Jong EM, de Haan MA, Gischler SJ, et al. Pre- and postnatal diagnosis and outcome of fetuses and neonates with esophageal atresia and tracheoesophageal fistula. *Prenat Diagn* 2010; **30**(3): 274-9.
24. Bower C, Rudy E, Callaghan A, Quick J, Nassar N. Age at diagnosis of birth defects. *Birth Defects Res A Clin Mol Teratol* 2010; **88**(4): 251-5.
25. Loane M, Dolk H, Morris JK, Group EW. Maternal age-specific risk of non-chromosomal anomalies. *BJOG : an international journal of obstetrics and gynaecology* 2009; **116**(8): 1111-9.
26. Balsells M, Garcia-Patterson A, Gich I, Corcoy R. Major congenital malformations in women with gestational diabetes mellitus: a systematic review and meta-analysis. *Diabetes/metabolism research and reviews* 2012; **28**(3): 252-7.
27. Correa A, Gilboa SM, Besser LM, et al. Diabetes mellitus and birth defects. *Am J Obstet Gynecol* 2008; **199**(3): 237 e1-9.
28. Oddsberg J, Lu Y, Lagergren J. Maternal diabetes and risk of esophageal atresia. *J Pediatr Surg* 2010; **45**(10): 2004-8.
29. Davies MJ, Moore VM, Willson KJ, et al. Reproductive technologies and the risk of birth defects. *N Engl J Med* 2012; **366**(19): 1803-13.

30. El-Chaar D, Yang Q, Gao J, et al. Risk of birth defects increased in pregnancies conceived by assisted human reproduction. *Fertil Steril* 2009; **92**(5): 1557-61.
31. Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk JJ. Assisted reproductive technologies and the risk of birth defects--a systematic review. *Hum Reprod* 2005; **20**(2): 328-38.
32. Hansen M, Kurinczuk JJ, Bower C, Webb S. The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. *N Engl J Med* 2002; **346**(10): 725-30.
33. Kallen B, Finnstrom O, Nygren KG, Olausson PO. In vitro fertilization (IVF) in Sweden: infant outcome after different IVF fertilization methods. *Fertil Steril* 2005; **84**(3): 611-7.
34. Reefhuis J, Honein MA, Schieve LA, Correa A, Hobbs CA, Rasmussen SA. Assisted reproductive technology and major structural birth defects in the United States. *Hum Reprod* 2009; **24**(2): 360-6.
35. Chittmittrapap S, Spitz L, Kiely EM, Brereton RJ. Oesophageal atresia and associated anomalies. *Arch Dis Child* 1989; **64**(3): 364-8.
36. Holland AJ, Fitzgerald DA. Oesophageal atresia and tracheo-oesophageal fistula: current management strategies and complications. *Paediatr Respir Rev* 2010; **11**(2): 100-6; quiz 6-7.
37. Yang CF, Soong WJ, Jeng MJ, et al. Esophageal atresia with tracheoesophageal fistula: ten years of experience in an institute. *J Chin Med Assoc* 2006; **69**(7): 317-21.

**Figure 1 - Prevalence of oesophageal atresia without (OA) or with tracheo-oesophageal fistula (OA+TOF) and tracheo-oesophageal fistula without oesophageal atresia (TOF), Western Australia, 1980-2009**



**Table 1: Number (%) of cases of oesophageal atresia without (OA) or with tracheo-oesophageal fistula (OA+TOF) and tracheo-oesophageal fistula without oesophageal atresia (TOF) in Western Australia, 1980-2009 by age at diagnosis**

Age at diagnosis	OA (n=26)			OA+TOF (n=202)						TOF (n=32)								
	1980-89	1990-99	2000-09	1980-89	1990-99	2000-09	1980-89	1990-99	2000-09	1980-89	1990-99	2000-09						
Prenatally	0	0%	1	17%	3	27%	3	6%	2	4%	7	7%	1	13%	2	15%	1	9%
Within the first week of life	7	78%	3	50%	1	9%	47	90%	42	76%	60	63%	5	63%	9	69%	9	82%
After the first week of life	1	11%	0	0%	0	0%	0	0%	0	0%	1	1%	2	25%	1	8%	1	9%
At postmortem examination	1	11%	2	33%	7	64%	2	4%	11	20%	27	28%	0	0%	1	8%	0	0%

**Table 2: Classification of oesophageal atresia without (OA) or with tracheo-oesophageal fistula (OA+TOF) and tracheo-oesophageal fistula without oesophageal atresia (TOF) cases, Western Australia, 1980-2009**

	OA (n=26)			OA+TOF (n=202)			TOF (n=32)		
	n	%	95% CI	n	%	95% CI	n	%	95% CI
Isolated	5	19.2	(8.5-37.9)	72	35.6	(29.4-42.5)	17	53.1	(36.4-69.1)
<i>Non-syndromic associated anomalies (*)</i>	8	30.8	(16.5-50.0)	59	29.2	(23.4-35.8)	6	18.8	(8.9-35.3)
Cardiovascular	3	11.5	(4.0-29.0)	36	17.8	(13.2-23.7)	4	1.8	(5.0-28.1)
Digestive	3	11.5	(4.0-29.0)	8	4.0	(2.0-7.6)	2	0.9	(1.7-20.1)
Genitourinary	1	3.8	(0.7-18.9)	16	7.9	(4.9-12.5)	1	0.4	(0.5-15.7)
Musculoskeletal	5	19.2	(8.5-37.9)	23	11.4	(7.7-16.5)	0	0.0	(0.0-10.7)
Central nervous system	2	7.7	(2.1-24.1)	6	3.0	(1.4-6.3)	0	0.0	(0.0-10.7)
Head and face	0	0.0	(0.0-12.9)	9	4.5	(2.4-8.2)	0	0.0	(0.0-10.7)
Respiratory system	0	0.0	(0.0-12.9)	4	2.0	(0.8-5.0)	1	0.4	(0.5-15.7)
Other	0	0.0	(0.0-12.9)	5	2.5	(1.1-5.7)	1	0.4	(0.5-15.7)
<i>Non-chromosomal recognized conditions</i>	7	26.9	(13.7-46.1)	50	24.8	(19.3-31.1)	7	21.9	(11.0-38.7)
Vacterl association	4	15.4	(6.1-33.5)	40	19.8	(14.9-25.8)	7	21.9	(11.0-38.7)
Oculo-auriculo-vertebral spectrum	0	0.0	(0.0-12.9)	1	0.5	(0.09-2.7)	0	0.0	(0.0-10.7)
Caudal dysplasia	0	0.0	(0.0-12.9)	3	1.5	(0.5-4.3)	0	0.0	(0.0-10.7)
Prune-belly sequence	1	3.8	(0.7-18.9)	2	1.0	(0.3-3.5)	0	0.0	(0.0-10.7)
Sirenomelia	1	3.8	(0.7-18.9)	1	0.5	(0.09-2.7)	0	0.0	(0.0-10.7)
Charge syndrome	0	0.0	(0.0-12.9)	3	1.5	(0.5-4.3)	0	0.0	(0.0-10.7)
Meckel Gruber syndrome	1	3.8	(0.7-18.9)	0	0.0	(0.0-1.9)	0	0.0	(0.0-10.7)
<i>Chromosomal associated malformations</i>	6	23.1	(11.0-42.0)	21	10.4	(6.9-15.4)	2	6.3	(1.7-20.1)
Down syndrome (Trisomy 21)	3	11.5	(4.0-29.0)	5	2.5	(1.1-5.7)	1	3.1	(0.5-15.7)
Edward syndrome (Trisomy 18)	2	7.7	(2.1-24.1)	15	7.4	(4.5-11.9)	1	3.1	(0.5-15.7)
Other chromosomal abnormalities	1	3.8	(0.7-18.9)	1	0.5	(0.09-2.7)	0	0.0	(0.0-10.7)

(\*) Numbers do not add to total as a case may have more than one associated congenital anomaly diagnosed

**Figure 2 - Prevalence of cases with associated anomalies and isolated cases of oesophageal atresia with or without tracheo-oesophageal fistula in Western Australia, 1980-2009**

